General Information of Drug Off-Target (DOT) (ID: OTG1GL9H)

DOT Name Low-density lipoprotein receptor class A domain-containing protein 1 (LDLRAD1)
Gene Name LDLRAD1
Related Disease
Breast cancer ( )
Prostate cancer ( )
Prostate carcinoma ( )
UniProt ID
LRAD1_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Pfam ID
PF00057
Sequence
MNKVFPQGENGYTAAESKAHPGGEAGGGHLCCSRRGACLSASLLLLLATVAALIALVTIL
GLPSCTPGAQACITLTNRTGFLCHDQRSCIPASGVCDGVRTCTHGEDEDESLCRDVPQSL
PHFLVAHCGDPASWIYSDQKCDGTNNCGDCSDELSPVTVCPPCGPGWWRCPSTFFKYCDC
IPRHLCRDHVQHCSDWSDEYACPGP

Molecular Interaction Atlas (MIA) of This DOT

3 Disease(s) Related to This DOT
Disease Name Disease ID Evidence Level Mode of Inheritance REF
Breast cancer DIS7DPX1 Strong Genetic Variation [1]
Prostate cancer DISF190Y Strong Genetic Variation [1]
Prostate carcinoma DISMJPLE Strong Genetic Variation [1]
------------------------------------------------------------------------------------
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
4 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Acetaminophen DMUIE76 Approved Acetaminophen increases the expression of Low-density lipoprotein receptor class A domain-containing protein 1 (LDLRAD1). [2]
Arsenic trioxide DM61TA4 Approved Arsenic trioxide increases the expression of Low-density lipoprotein receptor class A domain-containing protein 1 (LDLRAD1). [3]
Urethane DM7NSI0 Phase 4 Urethane decreases the expression of Low-density lipoprotein receptor class A domain-containing protein 1 (LDLRAD1). [4]
OTX-015 DMI8RG1 Phase 1/2 OTX-015 decreases the expression of Low-density lipoprotein receptor class A domain-containing protein 1 (LDLRAD1). [5]
------------------------------------------------------------------------------------
1 Drug(s) Affected the Post-Translational Modifications of This DOT
Drug Name Drug ID Highest Status Interaction REF
Benzo(a)pyrene DMN7J43 Phase 1 Benzo(a)pyrene affects the methylation of Low-density lipoprotein receptor class A domain-containing protein 1 (LDLRAD1). [6]
------------------------------------------------------------------------------------

References

1 Genome-wide testing of putative functional exonic variants in relationship with breast and prostate cancer risk in a multiethnic population.PLoS Genet. 2013 Mar;9(3):e1003419. doi: 10.1371/journal.pgen.1003419. Epub 2013 Mar 28.
2 Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
3 Endoplasmic reticulum stress contributes to arsenic trioxide-induced intrinsic apoptosis in human umbilical and bone marrow mesenchymal stem cells. Environ Toxicol. 2016 Mar;31(3):314-28.
4 Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
5 Comprehensive transcriptome profiling of BET inhibitor-treated HepG2 cells. PLoS One. 2022 Apr 29;17(4):e0266966. doi: 10.1371/journal.pone.0266966. eCollection 2022.
6 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.